Kalijn F Bol1, Thomas van den Bosch2, Gerty Schreibelt3, Hanneke W Mensink4, Jan E E Keunen5, Emine Kiliç6, Wouter J Japing7, Kaspar W Geul8, Harm Westdorp1, Steve Boudewijns1, Sandra A J Croockewit9, Michelle M van Rossum10, Anna L de Goede11, Nicole C Naus6, Winette T A van der Graaf12, Winald R Gerritsen13, Annelies de Klein14, Cornelis J A Punt15, Carl G Figdor3, Victoria M Cohen16, Dion Paridaens17, I Jolanda M de Vries18. 1. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. 2. Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands. 3. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. 4. Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands; Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands. 5. Department of Ophthalmology, Radboud University Medical Centre, Nijmegen, The Netherlands. 6. Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands. 7. Department of Ophthalmology, University Medical Center Groningen, Groningen, The Netherlands. 8. Department of Internal Medicine, Sint Franciscus Hospital, Rotterdam, The Netherlands. 9. Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands. 10. Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands. 11. Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands. 12. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Medical Oncology, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom. 13. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. 14. Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands. 15. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. 16. Department of Ophthalmology, Moorfields Eye Hospital and St. Bartholomew's Hospital, London, United Kingdom. 17. Department of Ocular Oncology, Rotterdam Eye Hospital, Rotterdam, The Netherlands; Department of Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands. 18. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands. Electronic address: Jolanda.deVries@radboudumc.nl.
Authors: Louis Cai; Manuel Paez-Escamilla; Scott D Walter; Bercin Tarlan; Christina L Decatur; Barbara M Perez; J William Harbour Journal: Am J Ophthalmol Date: 2018-08-06 Impact factor: 5.258
Authors: Mehdi Mazloumi; Pornpattana Vichitvejpaisal; Lauren A Dalvin; Antonio Yaghy; Kathryn G Ewens; Arupa Ganguly; Carol L Shields Journal: JAMA Ophthalmol Date: 2020-03-01 Impact factor: 7.389
Authors: Gülçin Gezgin; Mehmet Dogrusöz; T Huibertus van Essen; Wilhelmina G M Kroes; Gregorius P M Luyten; Pieter A van der Velden; Vonn Walter; Robert M Verdijk; Thorbald van Hall; Sjoerd H van der Burg; Martine J Jager Journal: Cancer Immunol Immunother Date: 2017-04-08 Impact factor: 6.968
Authors: Javier Rodriguez; Eduardo Castañón; Jose Luis Perez-Gracia; Inmaculada Rodriguez; Antonio Viudez; Carlos Alfaro; Carmen Oñate; Guiomar Perez; Fernando Rotellar; Susana Inogés; Ascensión López-Diaz de Cerio; Leyre Resano; Mariano Ponz-Sarvise; Maria E Rodriguez-Ruiz; Ana Chopitea; Ruth Vera; Ignacio Melero Journal: J Immunother Cancer Date: 2018-09-29 Impact factor: 13.751
Authors: Anja Wessely; Theresa Steeb; Michael Erdmann; Lucie Heinzerling; Julio Vera; Max Schlaak; Carola Berking; Markus Vincent Heppt Journal: Int J Mol Sci Date: 2020-01-29 Impact factor: 5.923